Content Type: Article

  • D&O Insurance – Issues to Consider Before a Claim Arises

    D&O Insurance – Issues to Consider Before a Claim Arises

    ARTICLE

    D&O Insurance – Issues to Consider Before a Claim Arises

    Fall 2016

    Read time: 2 min

    Key takeaways
    Overview

    Mark Collins and Joshua Rogaczewski wrote this bylined article on specific policy provisions to focus on when renewing or purchasing directors and officers insurance. “The best time to ensure that sufficient D&O insurance offered on the best available terms is in place is before a claim arises,” the authors wrote, because “a proactive approach when purchasing the policy can avoid delay, expense, and an unsatisfactory result if a claim arises.”

    In depth
    Authors

    Joshua David Rogaczewski

    Partner & Deputy General Counsel

    Washington, DC

    More insights

  • IP Update, Vol. 19, No. 9

    IP Update, Vol. 19, No. 9

    ARTICLE

    IP Update, Vol. 19, No. 9

    September 2016

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Paul Devinsky

    Senior Counsel

    Washington, DC

    More insights

  • Massachusetts Determination of Need Proposal Would Implement State Health Policy Initiatives in Updating DoN Regulations

    Massachusetts Determination of Need Proposal Would Implement State Health Policy Initiatives in Updating DoN Regulations

    ARTICLE / CLIENT ALERT

    Massachusetts Determination of Need Proposal Would Implement State Health Policy Initiatives in Updating DoN Regulations

    September 27, 2016

    Read time: 8 min

    Key takeaways
    Overview

    On September 21, the Massachusetts Department of Public Health conducted the first of two public hearings on proposed changes to the Determination of Need (DoN) regulations. The Proposal would implement significant changes impacting stakeholders in furtherance of the Department’s aim to simplify the DoN regulations and better align them with the public policy goals of improved access, quality and cost control. Public comments on the Proposal are due by October 7, 2016.

    In depth

    On September 21, the Massachusetts Department of Public Health (DPH or the Department) conducted the first of two public hearings on proposed changes to the Determination of Need (DoN) regulations (the Proposal). The Proposal would implement significant changes in furtherance of the Department’s aim to simplify the DoN regulations and better align them with the public policy goals of improved access, quality and cost control. Public comments on the Proposal are due by October 7, 2016. Now is the time to comment on these regulations, which have been a source of frustration for many stakeholders.

    1. System-Level Focus on DoN Applicant, “Holder” and Patient Panel

    The Proposal more closely aligns the DoN Program with the Health Policy Commission’s goals of “accountable care” via a system’s management of a defined patient population. For example, both the definition of DoN Applicant and the holder of the DoN now incorporate the term “Provider Organization,” as used in the HPC regulations. Only where there is no Provider Organization is the health care entity seeking the DoN for itself considered the “Applicant” and the “Holder” of the DoN, as in the past. The Proposal also includes an assessment of the impact of the project on the DoN Applicant’s “Patient Panel” (i.e., the total of individual patients seen over the course of the past 3 years) as part of the DoN process. This new focus on systems and wider population health concepts—rather than individual providers—could lead to some uncertainties in the assessment process, e.g., whether DoN modalities held by competitors would be discounted in the process.

    2. Opening the Window a Crack for ASCs for Hospitals and Hospital-Affiliated Joint Ventures

    The Proposal opens a small window of opportunity on the longstanding DoN moratorium on ambulatory surgery centers (ASCs), but in a manner that discriminates against applicants that are not hospital systems or hospital-affiliated joint ventures. Under the Proposal, DPH will only accept a new application for an ASC project when the DoN application is filed by an existing acute care hospital’s Provider Organization. The Proposal leaves no room for a new freestanding ASC that is not affiliated with a hospital or hospital system.

    3. DoN Review of Changes of Ownership

    Historically, Massachusetts DoN broadly defined a “change of ownership” (CHOW), and required a DoN for CHOWs of hospitals, their inpatient and outpatient satellites and clinics licensed as ambulatory surgery centers under an “alternate” or “expedited review” process for hospitals and ASCs. The Proposal completely eliminates this “alternate” or “expedited review” process, which has operated essentially as the exclusive DoN process for merger and acquisition transactions over the past many years. Subjecting all future CHOWs to the full review process under the Proposal, notwithstanding DPH’s assertions of streamlining the process, may pose a significant obstacle to obtaining timely approval for even routine CHOWs such as ones affecting financing or indirect changes of control. Of concern is the fact that the definition of a “change of ownership” or “transfer of ownership” has been removed from the Proposal as well. One thing that has not changed is the fact that the phrases “change of ownership” and “transfer of ownership” are still used interchangeably.

    The Proposal does not appear to take into account that, in some cases, a change of ownership is simply a change of indirect ownership or corporate restructuring that does not impact access to the facility or the services delivered by the facility. Indeed, in the past, some transactions that simply affected the financing or corporate structure of a health facility were treated as a CHOW subject to a DoN because of DPH’s broad definition of a CHOW. By way of contrast, in many of these types of transactions, Medicare does not consider it a “change of ownership” and only requires that information regarding the new indirect owners be filed.

    4. DoN Factors

    The materials accompanying the Proposal make a point that the current ten (10) regulatory factors are used to review the merits of a DoN application have been reduced to six. A textual comparison of the old factors with the factors in the Proposal suggests that is correct only with respect to the number of the factors designated by a separate Arabic number, and that the various subparts of the new factors in fact add more complexity. As noted above, these Factors now focus on systems-level population health concepts, health outcomes and price competition, as opposed to the current factors that refer to more general health planning objectives and service area duplication.

    Moreover, Factor 4 of the Proposal merits scrutiny as to the added level of assurance that the applicant must furnish, provided by a certified public accountant (CPA) under penalties of perjury, as to present and future financial performance of the applicant. This may create barriers for applicants, who may be unable to find CPAs willing to sign under this standard, or who may question whether they could even do so consistent with professional accounting standards.

    5. DoN Conditions, Post-Approval Reporting and Compliance Sanctions

    The DoN regulations currently contain extensive “Mandatory Terms and Conditions” imposed on each DoN Holder, which the Proposal continues and expands upon. Historically, the DoN holder has been required to expend, over a five-year period, an amount reasonably related to the cost of the project for the provision of primary and preventive health care services for underserved populations in the project’s service area in accordance with a plan submitted as part of the DoN application, as approved by the Department in the DoN process.

    The Proposal requires the DoN holder to expend over a five-year period (unless another period is specified by DPH), an amount in total greater than or equal to 5 percent of the total capital expenditure of the project in furtherance of the Department’s Community-Based Health Initiative Guideline, which will stand among the sub-regulatory guidance that the Department may issue under the Proposal without the benefit of a full public hearing process. The DoN Holder must report to DPH, at least on an annual basis, on “measures related to the project’s achievement” of the DoN Factors. If DoN Holder fails to sufficiently demonstrate compliance with this and all other Standard and Other Conditions of the DoN, the Proposal requires that the Holder fund projects that address Health Priorities set out in the Department’s Community-Based Health Initiative Guideline in an amount equal to 2.5 percent of the total capital expenditure of the approved project. It is unclear from the proposal how this 2.5 percent obligation that the Department can impose for non-compliances relates to the mandatory 5 percent or greater DoN condition. The 2.5 percent obligation and the ongoing reporting obligations are just a few examples in the panoply of post-DoN award reviews and sanctions that the Department can impose upon a Holder for non-compliance with mandatory or discretionary conditions. Furthermore, the Department reserves its ability to use of sub-regulatory guidelines and interpretational documents, which underscores the need for stakeholders to carefully monitor developments on an ongoing basis.

    6. DPH Plan Review of Projects

    Stating the goal of saving applicants significant time and costs, the Proposal combines DoN and facilities licensure “plan review” as concurrent processes. DPH plan review, which currently takes place as a two-step process, first before, and then after a DoN award, can be a lengthy and costly undertaking. Project scheduling and construction under the Proposal, however, may be made more complex in view of the extensive mandatory post-DoN award conditions (including coordination with the Department for review and approvals in project development and completion schedules), as it is still unclear from the Proposal how the process will actually be coordinated in practice.

    ***

    Testimony at the September 21 hearing indicates that the Proposal will be subject to lively discussion and debate on the Commonwealth’s regulation of the delivery of, and access to, health services. DPH is accepting comments on the proposal until October 7, 2016.

    Authors

    Charles R. Buck

    Partner

    Boston

    Sarah Kitchell

    Partner

    Boston

    More insights

  • The Perils of Parallel FCA Proceedings

    ARTICLE

    The Perils of Parallel FCA Proceedings

    September 23, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Tony Maida and Rebecca Martin wrote this bylined article on the recent increase in parallel civil and criminal False Claims Act proceedings by the US Justice Department. “From the defense side, parallel proceedings raise important and troublesome issues, including protecting the defendant’s Fifth Amendment rights while mounting a robust defense in the civil case,” the authors wrote, but added that “parallel proceedings may also prove challenging to the DOJ when a judge is impatient with the progress of the case.”

    In depth
    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • DOJ and OFAC Take Enforcement Action Against Canadian Payment Processor

    DOJ and OFAC Take Enforcement Action Against Canadian Payment Processor

    ARTICLE / CLIENT ALERT

    DOJ and OFAC Take Enforcement Action Against Canadian Payment Processor

    September 23, 2016

    Read time: 4 min

    Key takeaways
    Overview

    On Sept. 22, 2016, the Department of Justice (“DOJ”) and the Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) announced simultaneous actions against PacNet Services Ltd. (“PacNet”) — an international payments processor and U.S.-regulated money services business based in Vancouver, Canada — for allegedly facilitating fraudulent mass-mailing solicitations.[1] Most notably, OFAC designated the PacNet Group as a “transnational criminal organization,” or “TCO,” naming 12 of its executives and directors and 24 PacNet-affiliated companies worldwide as Specially Designated Nationals or “SDNs.” This designation has the effect of prohibiting U.S. persons[2] from engaging in transactions with PacNet and effectively eliminates PacNet’s access to the U.S. financial system. In addition, the government obtained a seizure warrant in the U.S. District Court for the Eastern District of New York for the funds in a PacNet U.S. bank account that is used to process payments received through allegedly fraudulent mailings.

    PacNet — a payment processor with operations in Canada, Ireland and the United Kingdom, and subsidiaries or affiliates in 15 other countries — is alleged to have knowingly processed payments for an international network of scam artists engaged in fraudulent mail solicitations targeting the elderly and other vulnerable victims. According to the government, PacNet has processed payments for the perpetrators of more than 100 different mail-fraud campaigns involving, in total, tens of millions of dollars. These include several mass-mailing operations that are the subject of separate criminal and civil law enforcement actions also announced yesterday.

    OFAC designated PacNet as a TCO pursuant to Executive Order (“E.O.”) 13581, “Blocking Property of Transnational Criminal Organizations.” As a result, all of PacNet’s property and interests in property that are in or come within the United States or come within the possession or control of any United States person, including any overseas branch, are blocked and may not be transferred, paid, exported, withdrawn or otherwise dealt in. President Obama issued E.O. 13581 in 2011 as a tool to break the economic power of transnational organized crime and protect financial markets, and to assist the Administration’s efforts to disrupt, dismantle and defeat the TCOs that pose a significant threat to U.S. national security, foreign policy or the economy. The designation of an international payments processor as a TCO is an unprecedented application of E.O. 13581, which previously has been used to impose sanctions on more conventional organized crime syndicates. In fact, PacNet is only the seventh TCO targeted under E.O. 13581. According to OFAC Acting Director John E. Smith, “Treasury will continue to use its authorities to respond to the evolving nature of transnational organized crime.”

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the following attorneys: Donald J. Mosher, Betty Santangelo, Gary Stein, Joseph P. Vitale, Seetha Ramachandran, Michael P. Court, Melissa G.R. Goldstein or Matthew J. Moses.


    [1] PacNet Services Ltd. is registered as a foreign-located money services business with the U.S. Department of the Treasury’s Financial Crimes Enforcement Network.

    [2] The term U.S. person means any U.S. citizen, permanent resident alien, entity organized under the laws of the United States or any jurisdiction within the United States (including non-U.S. offices or branches), or any person in the United States (including U.S. offices and subsidiaries of non-U.S. banks). See 31 C.F.R. § 590.314.


    This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors

    Donald J. Mosher

    Partner

    New York – 919 Third Avenue

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    More insights

  • Korea Quarterly

    Korea Quarterly

    ARTICLE

    Korea Quarterly

    September 2016

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • General Counsel’s Growing Prominence May Prompt Privilege Problems

    General Counsel’s Growing Prominence May Prompt Privilege Problems

    ARTICLE

    General Counsel’s Growing Prominence May Prompt Privilege Problems

    September 21, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Michael Peregrine and William Schuman wrote this bylined article on how the emerging best practice of granting general counsel greater organizational prominence can have the unintended consequence of weakening attorney-client privilege for the GC’s advice to management. “The burden of proof is placed on the party claiming the privilege, and courts often apply heightened scrutiny to communications to and from in-house counsel,” the authors wrote.

    In depth
    Authors
    More insights

  • Ninth Circuit Insulates California Tax Sale from Fraudulent Transfer Attack

    Ninth Circuit Insulates California Tax Sale from Fraudulent Transfer Attack

    ARTICLE / CLIENT ALERT

    Ninth Circuit Insulates California Tax Sale from Fraudulent Transfer Attack

    September 21, 2016

    Read time: 7 min

    Key takeaways
    Overview

    “[T]he price received at a California tax sale” properly held under state law “conclusively establishes ‘reasonably equivalent value’ for purposes of” the Bankruptcy Code’s (“Code”) fraudulent transfer section (§ 548(a)(1)), held the U.S. Court of Appeals for the Ninth Circuit on Sept. 8, 2016. In re Tracht Gut LLC, 2016 WL4698300, at *1 (9th Cir. Sept. 8, 2016). Affirming the lower courts, the Ninth Circuit reasoned that “California tax sales have the same procedural safeguards as the California mortgage foreclosure sale” approved by the U.S. Supreme Court in BFP v. Resolution Trust Corp., 511 U.S. 531, 533, 545 (1994) (held, price received at mortgage foreclosure sale “conclusively satisfies” Code’s requirement that transfer of insolvent debtor’s property be in exchange for “reasonably equivalent value” so long as mortgagee complied with relevant foreclosure laws of state in question, i.e., California).

    Relevance

    A transfer by an insolvent or inadequately capitalized debtor is constructively fraudulent under Code § 548(a)(1)(B) if made for “less than a reasonably equivalent value” and within two years of bankruptcy. Because the debtor in Tracht Gut was apparently insolvent, the “central” question was whether the proceeds of the tax sale constituted “reasonably equivalent value” under Code § 548(a). 2016 WL4698300, at *1. Prior to the Supreme Court’s 1994 BFP ruling, appellate courts had been split on whether the proceeds of the foreclosure sale could ever constitute “reasonably equivalent value.” See, e.g., Durrett v. Wash. Nat’l Ins. Co., 621 F.2d 201 (5th Cir. 1980) (rigid mathematical approach requiring that at least 70 percent of fair-market value be realized); In re Bundles, 856 F.2d 815, 824 (7th Cir. 1988) (facts considered include fair appraisal of property, range of advertisements and competitiveness of bids). Although BFP resolved the value issue with respect to real estate mortgage foreclosure sales, the Supreme Court limited its holding to that context because the “considerations bearing upon other foreclosures and forced sales (to satisfy tax liens, for example) may be different.” BFP, 511 U.S. at 537 n.3. As shown below, courts have also applied the reasoning of BFP even when a bankruptcy trustee seeks to undo a pre-bankruptcy matrimonial decree.

    Facts

    The debtor purchased two parcels of real estate in 2012 for $60,000, “subject to three deeds of trust” and four years of unpaid real property taxes. 2016 WL4698300, at *1-*2. Because both parcels were “tax defaulted,” the County Treasurer (“County”) later conducted tax sales of the properties under California law. After a public auction, two buyers bought each parcel, one for $300,000, and the other for $100,000.

    The debtor filed its Chapter 11 petition a month after the tax sales. It promptly sued the County and the two buyers of the properties, asserting, among other things, that “the sales were fraudulent transfers” under Code § 548 because “the sales price [for each parcel] was too low.” Id. at *6. The bankruptcy court dismissed the complaint for failure to state a claim for relief, and the Bankruptcy Appellate Panel (“BAP”) affirmed, relying on the Supreme Court’s BFP opinion, and reasoning that it should also apply “to tax sales under California law.” Id. at *2.

    Analysis

    The Ninth Circuit agreed with the BAP, stating that “the rationale and policy considerations behind … BFP are just as relevant in the California tax sale context.” Id. at *4. It conceded that the Supreme Court had “expressly limited [its] holding to mortgage foreclosures of real estate.” Agreeing with the BAP, though, the court explained why BFP “should also apply to tax sales in California.”

    Market Value Not Relevant

    The court rejected the debtor’s argument that the foreclosure sales price “was too low when compared to market value.” Id. at *5. As the Supreme Court explained, “market value, as it is commonly understood, has no applicability in the forced-sale context,” because market value “is the very antithesis of forced-sale value.” BFP, 511 U.S. at 537. Indeed, “state law allows the forced sales of real estate,” meaning that “property sold at such sales is ‘simply worth less’ than property ‘sold at leisure and pursuant to normal marketing techniques.’” 2016 WL 4698300, at *5, citing BFP, 511 U.S. at 539. In other words, “the lower price obtained at a foreclosure sale, when compared to a fair-market valuation, is a result of the mechanism of forced sales …. ” Id. Thus, “if debtors were able to avoid mortgage foreclosures under federal bankruptcy laws simply because the property was sold below market value at the foreclosure sale, the state regulatory regime in which creditors can conduct forced sales on foreclosed property would be frustrated.” Id., citing BFP, at 537-39.

    State Law Key

    The Ninth Circuit stressed that “tax foreclosure sales conducted by state and local governments are governed by state law.” For that reason, the “same procedural safeguards under California law that led the Supreme Court [in BFP] to conclude that mortgage foreclosures would yield reasonably equivalent value are also required in California for tax sales.” Id. The California tax sale procedure required “notice to the defaulting borrower, a substantial lead time before the commencement of foreclosure proceedings, publication of a notice of sale and strict adherence to prescribed bidding rules and auction procedures.” Id., quoting BFP, 511 U.S. at 542. Finally, California law “requires that all tax sales shall be at public auction to the highest bidder.” Id.

    Other Contexts

    The Ninth Circuit had previously extended the BFP analysis “beyond the context of mortgage foreclosures.” See, e.g., Batlan v. Bledsoe (In re Bledsoe), 569 F.3d 1106, 1112 (9th Cir. 2009) (Chapter 11 debtor spouse’s bankruptcy trustee sued non-debtor spouse, seeking to avoid purportedly “inequitable” property transfer required by marital dissolution judgment; relying on BFP, held, “a state court’s dissolution judgment, following a regularly conducted contested proceeding, conclusively established ‘reasonably equivalent value’ for purpose of § 548, in the absence of actual fraud”; “state’s traditional interest in the regulation of marriage and divorce is at least as powerful as its traditional interest in regulating sales of real property”; “[a]voiding transfers made pursuant to a state-court dissolution judgment would seriously impinge on that traditional state interest.”). Accord, In re Erlewine, 349 F.3d 205, 212-213 (5th Cir. 2003) (same; divorce “fully litigated”; despite unequal division of property, debtor received reasonably equivalent value).

    Other Circuits

    The Fifth and Tenth Circuits also have applied BFP to tax sales. In re T.F. Stone Co., 72 F.3d 466, 472 (5th Cir. 1995) (held, tax sale complying with state law satisfied “present fair equivalent value” requirement consistent with “reasonably equivalent value” requirement of § 548); In re Grandote Country Club Ltd., 252 F.3d 1146, 1152 (10th Cir. 2001) (held, BFP applies to tax sales challenged under state fraudulent transfer law when state law requires competitive bidding procedures).

    The debtor only argued that the “sales price was too low,” but failed to “allege any procedural defects with … the tax sales …. ” 2016 WL 4698300, at *6. In short, the court properly presumed “that the price received at the tax sale was for reasonably equivalent value absent procedural irregularity” under applicable state law. Id.

    Authored by Michael L. Cook.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or the author.


    This information has been prepared by Schulte Roth & Zabel LLP (“SRZ”) for general informational purposes only. It does not constitute legal advice, and is presented without any representation or warranty as to its accuracy, completeness or timeliness. Transmission or receipt of this information does not create an attorney-client relationship with SRZ. Electronic mail or other communications with SRZ cannot be guaranteed to be confidential and will not (without SRZ agreement) create an attorney-client relationship with SRZ. Parties seeking advice should consult with legal counsel familiar with their particular circumstances. The contents of these materials may constitute attorney advertising under the regulations of various jurisdictions.

    In depth
    Authors
    More insights

  • Proof of Facts in SALT Cases: Do’s and Don’ts

    ARTICLE

    Proof of Facts in SALT Cases: Do’s and Don’ts

    September 19, 2016

    Read time: 2 min

    Key takeaways
    Overview

    Peter Faber wrote this bylined article emphasizing the care practitioners should take to establish the facts of their tax controversy case. “I have seen all too many situations in which taxpayer advocates have not treated the proof of facts carefully or systematically,” Mr. Faber wrote. “They have not realized that they have the burden of proof and that department officials will not be satisfied with simply receiving the unsupported statements of an accountant or a lawyer as to what the facts were.”

    In depth
    Authors
    More insights

  • FDA Announces Public Hearing on Off-Label Communications; Registration Deadline October 19, 2016

    FDA Announces Public Hearing on Off-Label Communications; Registration Deadline October 19, 2016

    ARTICLE / CLIENT ALERT

    FDA Announces Public Hearing on Off-Label Communications; Registration Deadline October 19, 2016

    September 19, 2016

    Read time: 4 min

    Key takeaways
    Overview

    The US Food and Drug Administration (FDA) will hold a public hearing on November 9 and 10, 2016, to obtain input on manufacturer communications regarding unapproved uses of approved or cleared medical products (off-label promotions).

    In depth

    The US Food and Drug Administration (FDA) will hold a public hearing on November 9 and 10, 2016, to obtain input on manufacturer communications regarding unapproved uses of approved or cleared medical products (off-label promotions).

    FDA has broad authority to proscribe the content of product labeling and impose restrictions on the off-label promotion of drugs, medical devices and other regulated products. However, the First Amendment to the US Constitution and other laws restrict the extent to which FDA can prohibit truthful and non-misleading statements about unapproved or off-label uses of such products. Despite well-established constitutional protections on the dissemination of scientific speech and truthful and non-misleading commercial speech, the number of prosecutions, indictments and settlements arising from off-label promotion of drugs and medical devices has increased significantly in the past ten years. The number of warning letters related to unapproved use of medical devices and off-label claims for drugs has also increased in the same timeframe. Manufacturers and other stakeholders have called for additional guidance and greater limits on FDA’s application of speech-related enforcement principles, such as the “intended use” doctrine, to hold companies liable for the dissemination of truthful and non-misleading claims regarding off-label uses or unapproved uses of medical devices and other products.

    In response to recent speech-related court decisions such as United States v. Caronia, 703 F.3d 149 (2d Cir. 2012) (holding that the government may not prohibit or criminalize truthful off-label promotional speech); Amarin Pharma, Inc. v. FDA, 119 F. Supp. 3d 196 (S.D.N.Y. 2015) (holding that the government may not pursue misbranding provisions under the Federal Food, Drug and Cosmetic Act for statements that were truthful and non-misleading); and United States v. Vascular Solutions, Inc., Cr. No. 14-926 (W.D. Tex. 2016) (jury finding that speech that is “solely truthful and not misleading” cannot be basis for misbranding charge), FDA is requesting public comment on the regulation of manufacturer communications regarding off-label or unapproved uses of approved medical products. FDA intends to address and prioritize “Manufacturer Communications Regarding Unapproved, Unlicensed, or Uncleared Uses of Approved, Licensed, or Cleared Human Drugs, Biologics, Animal Drugs and Medical Devices” in a guidance document.

    The agency is requesting comments from stakeholders on the following broad questions:

    (1) How increased off-label promotions could impact public health, and whether the impact would differ across different categories of medical products

    (2) The extent to which increased off-label promotion would affect incentives for firms to seek FDA approval or clearance for new uses

    (3) The effect of increased availability of information regarding unapproved uses on firms’ incentives to seek FDA approval or clearance for new uses

    (4) Standards the agency should apply to off-label communications to minimize the potential that they are misleading or harmful

    (5) Factors the agency should consider in evaluating whether off-label promotions are truthful and non-misleading

    (6) Whether firms should disclose data from human studies to ensure quality and integrity of communications and scientific information, and how transparency of this information should be monitored

    (7) How the agency should monitor off-label promotions and what actions it should take with respect to those that are false or misleading or otherwise raise public health issues

    (8) Changes FDA should consider to 21 C.F.R. §§ 201.128 and 801.4 pursuant to its notice of proposed rulemaking

    The hearing is an important step in what will undoubtedly be a longer-term process of reconciling FDA’s product approval process and speech restrictions with evolving First Amendment precedent. The hearing is a meaningful opportunity for manufacturers, marketers and other stakeholders to provide information, data and feedback to FDA on critical issues that will shape future policies on marketing communications. Comments may be submitted online.

    Important Dates and Information

    Registration Deadline: October 19, 2016

    Public Hearing Dates: November 9 and 10, 2016

    FDA White Oak Campus
    10903 New Hampshire Avenue
    Bldg. 31, Great Room (Rm. 1503)
    Silver Spring, MD 20993

    Authors
    More insights